Adherence to cardiovascular therapy: A meta-analysis of prevalence and clinical consequences

European Heart Journal

Volumn 34, Issue 38, 2013, Pages 2940-2948

  Chowdhury, Rajiv ^a   Khan, Hassan ^a   Heydon, Emma ^a   Shroufi, Amir ^a   Fahimi, Saman ^a   Moore, Carmel ^a   Stricker, Bruno ^b   Mendis, Shanthi ^c   Hofman, Albert ^b   Mant, Jonathan ^a   Franco, Oscar H ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cardiovascular disease; Medication adherence

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; EMBASE; HUMAN; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; RISK FACTOR; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; ADVERSE OUTCOME; CARDIOVASCULAR MORTALITY; FATALITY; PREVALENCE; RISK ASSESSMENT;

CARDIOVASCULAR DISEASE; MEDICATION ADHERENCE;

ADULT; AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EPIDEMIOLOGIC METHODS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; YOUNG ADULT;

EID: 84885965367     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht295     Document Type: Article

References (39)

1. Osterberg L, BlaschkeT. Adherence to medication.NEngl JMed2005;353:487-497.
2. Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, Daniel JG, Ekman I, Ho M, Johnson M, Kimmel SE, Liu LZ, Musaus J, Shrank WH, Whalley Buono E, Weiss K, Granger CB. Medication adherence: A call for action. Am Heart J 2011;162:412-424.
3. Cutler DM, EverettW. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010;362:1553-1555.
4. Adherence to Long-Term Therapies-Evidence for Action [Internet]. WHO; 2003 (4 May 2012). Available from: Http://apps.who.int/medicinedocs/en/d/ Js4883e/(29 July 2013).
5. Marcum ZA, Sevick MA, Handler SM. Medication nonadherence: A diagnosable and treatable medical condition. JAMA 2013;309:2105-2106.
6. Ascertaining Barriers for Compliance: Policies for Safe, Effective and Cost-effective Use of Medicines in Europe. ABC Project newsletter [Internet]. 2009; Available from: Http://abcproject.eu/img/ABC-newsletter-06-03-2009.pdf (29 July 2013).
7. Sabaté E. Adherence to Long-Term TherapiesdEvidence for Action. Geneva. World Health Organization; 2003.
8. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-1336.
9. Senst BL, Achusim LE, Genest RP, Cosentino LA, Ford CC, Little JA, Raybon SJ, Bates DW. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126-1132.
10. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-2313.
11. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis. JAMA 2011;305:913-922.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, JonesDW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
13. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.Arandomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
14. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009;119:3028-3035.
15. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980- 2000. N Engl J Med 2007;356:2388-2398.
16. Naderi SH, Bestwick JP,Wald DS. Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376 162 patients. Am J Med 2012;125:882-887.e1.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
19. Peterson AM, NauDP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M.Achecklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
20. Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996; 144:610-621.
21. Mladovsky P, Allin S, Masseria C, Hernández-Quevedo C, McDaid D, Mossialos E. Health in the European Union: Trends and analysis.World Health Organization on behalf of the European Observatory on Health Systems and Policies, Copenhagen, Denmark, 2009, ISBN 9789289041904.
22. Rothman K, Greenland S. Modern Epidemiology, 2nd ed. Lippincott Williams & Wilkins: Philadelphia, 1998.
23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
24. Begg CB. A measure to aid in the interpretation of published clinical trials. Stat Med 1985;4:1-9.
25. Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, Garc?́a-Del Blanco B, Mart?́ G, Cascant P, Masotti-Centol M, Carrillo X, Mauri J, Batalla N, Larrousse E, Mart?́n E, Serra A, Rumoroso JR, Ruiz-Salmerón R, De la Torre JM, Cequier A, Gómez-Hospital JA, Alfonso F, Mart?́n-Yuste V, Sabatè M, Garc?́a-Dorado D. Double antiplatelet therapy after drug-eluting stent implantation: Risk associated with discontinuation within the first year. J Am Coll Cardiol 2012;60:1333-1339.
26. BowryADK, Shrank WH, Lee JL, StedmanM, Choudhry NK. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med 2011;26:1479-1491.
27. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA. Statin adherence and risk of accidents: A cautionary tale. Circulation 2009;119:2051-2057.
28. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. Ameta-analysis of the association between adherence to drug therapyand mortality. BMJ 2006;333:15.
29. LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: A case study in healthy user bias and hypertension. Heart 2011;97: 1862-1869.
30. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidencebased pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-186.
31. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ. Placebo adherence, clinical outcomes, and mortality in the women'S health initiative randomized hormone therapy trials. Med Care 2011;49:427-435.
32. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008;371:117-125.
33. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels amongUSadults: Impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208-1215.
34. American heart association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American heart association; 2001.
35. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289: 1107-1116.
36. Hudson M, Rahme E, Richard H, Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007;153:59-65.
37. Dragomir A, Cô té R, Roy L, Blais L, Lalonde L, Bérard A, Perreault S. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010;48:418-425.
38. ClyneW, Mshelia C, Hall S, McLachlan S, Jones P, Dobbels F, Ruppar T, Siebens K, MorrisonV, Geest S,DeKardas P. Management of patient adherence to medications: Protocol for an online survey of doctors, pharmacists and nurses in Europe. BMJ Open 2011;1:e000355.
39. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007 85 279-288.